Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;12(2):e220193.
doi: 10.2217/cer-2022-0193. Epub 2023 Jan 27.

Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain

Ricardo Ginestal  1 , Carlos Rubio-Terrés  2 , Olga Durán Morán  3 , Darío Rubio-Rodríguez  2 , Heidi De Los Santos  3 , Cristina Ordoñez  3 , Isabel Sánchez-Magro  3
Affiliations

Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain

Ricardo Ginestal et al. J Comp Eff Res. 2023 Feb.

Abstract

Aim: To analyze the cost-effectiveness of treatment of relapsing remitting multiple sclerosis (RRMS) with cladribine tablets (CladT) and dimethyl fumarate (DMF) from the perspective of the Spanish National Health System (NHS). Methods: A probabilistic Markov model (second-order Monte Carlo simulation) with a 10-year time horizon and annual Markov cycles was performed. Results: CladT was the dominant treatment, with lower costs (-74,741 € [95% CI: -67,247; -85,661 €]) and greater effectiveness (0.1920 [95% CI: -0.1659; 0.2173] QALY) per patient, compared with DMF. CladT had a 95.1% probability of being cost-effective and a 94.1% chance of being dominant compared with DMF. Conclusion: CladT is the dominant treatment (lower costs, with more QALYs) compared with DMF in the treatment of RRMS in Spain.

Keywords: cladribine tablets; cost–effectiveness; dimethyl fumarate; multiple sclerosis; relapsing-remitting multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Figures

Figure 1.
Figure 1.. Five-state Markov model, adapted from a model of the Canadian Agency for Drugs and Technologies in Health and the Norwegian Institute of Public Health [16,18].
Patients with relapsing remitting multiple sclerosis. EDSS: Expanded Disability Status Scale.
Figure 2.
Figure 2.. Incremental cost–effectiveness plane of cladribine tablets versus dimethyl fumarate.
EUR: Euros; ICE: Incremental cost–effectiveness ratio; QALY: Quality-adjusted life years; WTP: Willingness to pay to gain one QALY: 25,000 €.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Montalban X, Gold R, Thompson AJ et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler. 24, 96–120 (2018). - PubMed
    1. MSSSI: Ministerio de Sanidad, Servicios Sociales e Igualdad. Estrategia en Enfermedades Neurodegenerativas del Sistema Nacional de Salud (2016). Available from: www.msps.es/organizacion/sns/planCalidadSNS/pdf/Est_Neurodegenerativas_A... (Accessed December 2021).
    1. Bártulos M, Marzo ME, Estrella LA, Bravo Y. Estudio epidemiológico de la esclerosis múltiple en La Rioja. Neurología 30, 552–560 (2015). - PubMed
    1. Izquierdo G, Venegas A, Sanabria C, Navarro G. Long-term epidemiology of multiple sclerosis in the Northern Seville District. Acta Neurol. Scand. 132, 111–117 (2015). - PMC - PubMed
    1. Carreón-Guarnizo E, Andreu-Reinón E, Cerdán-Sánchez M et al. Prevalencia de la esclerosis múltiple en la Región de Murcia. Rev. Neurol. 62, 396–402 (2016). - PubMed

MeSH terms